These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 23018309

  • 1. Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.
    Zhang Y, Zhang B, Zhang A, Zhao Y, Zhao J, Liu J, Gao J, Fang D, Rao Z.
    Clinics (Sao Paulo); 2012 Sep; 67(9):1093-9. PubMed ID: 23018309
    [Abstract] [Full Text] [Related]

  • 2. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
    Wei G, Wang M, Hyslop T, Wang Z, Carr BI.
    Int J Cancer; 2010 Dec 15; 127(12):2949-58. PubMed ID: 21351273
    [Abstract] [Full Text] [Related]

  • 3. Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.
    Jiang X, Feng K, Zhang Y, Li Z, Zhou F, Dou H, Wang T.
    Oncotarget; 2015 May 20; 6(14):12340-56. PubMed ID: 25895026
    [Abstract] [Full Text] [Related]

  • 4. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
    You A, Cao M, Guo Z, Zuo B, Gao J, Zhou H, Li H, Cui Y, Fang F, Zhang W, Song T, Li Q, Zhu X, Yin H, Sun H, Zhang T.
    J Hematol Oncol; 2016 Mar 08; 9():20. PubMed ID: 26957312
    [Abstract] [Full Text] [Related]

  • 5. Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
    D'Alessandro R, Refolo MG, Lippolis C, Carella N, Messa C, Cavallini A, Carr BI.
    Cell Oncol (Dordr); 2018 Jun 08; 41(3):283-296. PubMed ID: 29470830
    [Abstract] [Full Text] [Related]

  • 6. Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
    Deng L, Ren Z, Jia Q, Wu W, Shen H, Wang Y.
    BMC Cancer; 2013 Jul 29; 13():363. PubMed ID: 23895220
    [Abstract] [Full Text] [Related]

  • 7. Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
    Morisaki T, Umebayashi M, Kiyota A, Koya N, Tanaka H, Onishi H, Katano M.
    Anticancer Res; 2013 Apr 29; 33(4):1387-95. PubMed ID: 23564777
    [Abstract] [Full Text] [Related]

  • 8. Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis.
    Ha TY, Hwang S, Hong HN, Choi YI, Yoon SY, Won YJ, Song GW, Kim N, Tak E, Ryoo BY.
    Anticancer Res; 2015 Apr 29; 35(4):1985-95. PubMed ID: 25862851
    [Abstract] [Full Text] [Related]

  • 9. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
    Kong J, Kong F, Gao J, Zhang Q, Dong S, Gu F, Ke S, Pan B, Shen Q, Sun H, Zheng L, Sun W.
    Mol Cancer; 2014 Jan 13; 13():7. PubMed ID: 24418169
    [Abstract] [Full Text] [Related]

  • 10. A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
    Hu B, Sun D, Sun C, Sun YF, Sun HX, Zhu QF, Yang XR, Gao YB, Tang WG, Fan J, Maitra A, Anders RA, Xu Y.
    Biochem Biophys Res Commun; 2015 Dec 25; 468(4):525-32. PubMed ID: 26482853
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
    Alsaied OA, Sangwan V, Banerjee S, Krosch TC, Chugh R, Saluja A, Vickers SM, Jensen EH.
    Surgery; 2014 Aug 25; 156(2):270-9. PubMed ID: 24953273
    [Abstract] [Full Text] [Related]

  • 12. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M, Fei Z, Zhang G.
    Biomed Pharmacother; 2018 Jan 25; 97():1282-1288. PubMed ID: 29156516
    [Abstract] [Full Text] [Related]

  • 13. Synergistic Antitumor Effect of Sorafenib in Combination with ATM Inhibitor in Hepatocellular Carcinoma Cells.
    Liu J, Liu Y, Meng L, Ji B, Yang D.
    Int J Med Sci; 2017 Jan 25; 14(6):523-529. PubMed ID: 28638267
    [Abstract] [Full Text] [Related]

  • 14. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Yang Y, Jiang H, Gao H, Kong J, Zhang P, Hu S, Shi B, Zhang P, Yao M, Li Z.
    Neoplasia; 2012 Jun 25; 14(6):509-18. PubMed ID: 22787432
    [Abstract] [Full Text] [Related]

  • 15. Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
    Chen KF, Chen HL, Shiau CW, Liu CY, Chu PY, Tai WT, Ichikawa K, Chen PJ, Cheng AL.
    Br J Pharmacol; 2013 Feb 25; 168(3):658-72. PubMed ID: 22978563
    [Abstract] [Full Text] [Related]

  • 16. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
    Zhai JM, Yin XY, Lai YR, Hou X, Cai JP, Hao XY, Liang LJ, Zhang LJ.
    Cancer Chemother Pharmacol; 2013 May 25; 71(5):1255-64. PubMed ID: 23435877
    [Abstract] [Full Text] [Related]

  • 17. Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.
    Wan J, Liu T, Mei L, Li J, Gong K, Yu C, Li W.
    Br J Cancer; 2013 Jul 23; 109(2):342-50. PubMed ID: 23807172
    [Abstract] [Full Text] [Related]

  • 18. Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
    Chen CH, Chen MC, Wang JC, Tsai AC, Chen CS, Liou JP, Pan SL, Teng CM.
    Clin Cancer Res; 2014 Mar 01; 20(5):1274-1287. PubMed ID: 24520095
    [Abstract] [Full Text] [Related]

  • 19. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
    Hsu C, Lin LI, Cheng YC, Feng ZR, Shao YY, Cheng AL, Ou DL.
    Clin Cancer Res; 2016 May 15; 22(10):2555-64. PubMed ID: 26603262
    [Abstract] [Full Text] [Related]

  • 20. Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation.
    Yan Y, Wang L, He J, Liu P, Lv X, Zhang Y, Xu X, Zhang L, Zhang Y.
    Biomed Pharmacother; 2017 Apr 15; 88():395-402. PubMed ID: 28122304
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.